Last update Aug. 24, 2022
Very Low Risk
We do not have alternatives for 抗血友病因子 ; 艾芙莫罗凝血素α ; 莫罗凝血素α ; 辛凝血素α ; 培罗辛凝血素α ; 塞莫凝血素α ; 舒索凝血素α ; 妥罗凝血素α since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
抗血友病因子 ; 艾芙莫罗凝血素α ; 莫罗凝血素α ; 辛凝血素α ; 培罗辛凝血素α ; 塞莫凝血素α ; 舒索凝血素α ; 妥罗凝血素α is Coagulation Factor VIII, Antihemophilic Factor (AHF) in Chinese.Is written in other languages:
抗血友病因子 ; 艾芙莫罗凝血素α ; 莫罗凝血素α ; 辛凝血素α ; 培罗辛凝血素α ; 塞莫凝血素α ; 舒索凝血素α ; 妥罗凝血素α is also known as
抗血友病因子 ; 艾芙莫罗凝血素α ; 莫罗凝血素α ; 辛凝血素α ; 培罗辛凝血素α ; 塞莫凝血素α ; 舒索凝血素α ; 妥罗凝血素α belongs to this group or family:
Main tradenames from several countries containing 抗血友病因子 ; 艾芙莫罗凝血素α ; 莫罗凝血素α ; 辛凝血素α ; 培罗辛凝血素α ; 塞莫凝血素α ; 舒索凝血素α ; 妥罗凝血素α in its composition:
|VD||0.03 - 0.04||l/Kg|
|Tmax||14.8 (12 - 20)||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Coagulation factor IX or Antihemophilic Factor is a plasma glycoprotein consisting of 2,300 amino acids that is used to treat hemophilia B (factor VIII deficiency). It can be obtained from human plasma or produced by recombinant DNA technology (Efmoroctocog Alfa, Moroctocog Alfa, Octocog Alfa, Rurioctocog Alfa, Simoctocog Alfa, Susoctocog alfa, Turoctocog Alfa ), or as a pegylated derivative (Rurioctocog Alfa Pegol). Intravenous administration.
Since the last update we have not found published data on its excretion in breastmilk.
Its very high molecular weigh make it highly unlikely that significant quantities will pass into breast milk.
Due to its protein nature, it is inactivated in the gastrointestinal tract, and is not absorbed, (it has virtually no oral bioavailability), which hinders or prevents its transfer from breastmilk to infant, except in premature babies and the immediate neonatal period, when there may be greater intestinal permeability.
Expert authors consider the use of this medication probably compatible during breastfeeding. (Hale). Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs: compatible with Breastfeeding. (WHO 2002)